List of Excipients in Branded Drug ACTIGALL

ACTIGALL Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Actigall is the branded ursodiol product used for primary biliary cholangitis and dissolution of radiolucent cholesterol gallstones. Its commercial opportunity is not based on biologic exclusivity or a durable patent moat. The stronger opportunities are in patient-friendly oral dosage forms, excipient simplification, pediatric and dysphagia products, supply-chain differentiation, and branded-generic positioning.

The main excipient targets are capsule swallowability, powder flow, dissolution consistency, colorant reduction, allergen control, and liquid-suspension stability. A new product would likely compete through formulation performance and regulatory execution rather than through composition-of-matter patents.

What is Actigall and how is it used?

Actigall contains ursodiol, also called ursodeoxycholic acid. It is administered orally for:

• Dissolution of certain cholesterol gallstones in patients who are not suitable candidates for surgery.
• Reduction of liver damage in patients with primary biliary cholangitis.
• Certain off-label hepatobiliary and pediatric uses under specialist supervision.

Actigall is a small-molecule prescription drug. It is not a biologic and therefore has no biosimilar pathway. Generic approval is generally pursued under an abbreviated new drug application, subject to the reference product’s approved dosage form, strength, labeling, and bioequivalence requirements.[1,2]

Actigall dosage forms and strengths

Product	Active ingredient	Strength	Route	Commercial relevance
Actigall capsule	Ursodiol	300 mg	Oral	Established reference product
Ursodiol tablet products	Ursodiol	250 mg, 500 mg	Oral	Generic and alternative dosage-form competition
Compounded suspensions	Ursodiol	Variable	Oral	Pediatric and dysphagia opportunity
Potential commercial suspension	Ursodiol	25-50 mg/mL range	Oral	Formulation and stability opportunity

The approved dose is indication- and patient-specific. PBC dosing is commonly weight-based, while gallstone dissolution therapy can require prolonged treatment. That dosing profile creates an opportunity for flexible liquid delivery and smaller unit doses.[1]

What excipients are used in Actigall capsules?

The Actigall 300 mg capsule label identifies a conventional solid-oral excipient system. Listed inactive ingredients include microcrystalline cellulose, povidone, crospovidone, sodium starch glycolate, magnesium stearate, talc, colloidal silicon dioxide, gelatin, titanium dioxide, and colorants including D&C Yellow No. 10 and FD&C Blue No. 1.[1]

Functional role of the Actigall excipients

Excipient	Primary function	Formulation consideration
Microcrystalline cellulose	Diluent and compressibility aid	Supports capsule fill uniformity
Povidone	Binder	Improves granule or powder cohesion
Crospovidone	Superdisintegrant	Accelerates capsule-content dispersion
Sodium starch glycolate	Superdisintegrant	Supports dissolution after capsule opening
Magnesium stearate	Lubricant	Excess can reduce wetting and dissolution
Colloidal silicon dioxide	Glidant	Improves powder flow
Talc	Processing aid and anti-adherent	Requires control of particle quality
Gelatin	Capsule shell	Creates animal-origin, allergen, and vegetarian-positioning issues
Titanium dioxide	Opacifier	Subject to regional regulatory and consumer scrutiny
D&C Yellow No. 10, FD&C Blue No. 1	Colorants	Can be removed for clean-label or regional strategies

The formulation is commercially conventional. No single listed excipient creates a substantial barrier to generic development. Competitive value is more likely to arise from process control, excipient selection, capsule-shell design, stability, and patient usability.

What excipient strategy is most attractive for an Actigall competitor?

A commercially attractive strategy would preserve ursodiol’s dissolution performance while reducing avoidable formulation complexity.

1. Simplify the capsule platform

A generic or branded-generic developer could evaluate a capsule containing ursodiol with microcrystalline cellulose, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate. Removing colorants, titanium dioxide, talc, or povidone may support:

• Lower excipient count.
• Reduced supplier qualification burden.
• Easier regional registration.
• Improved clean-label marketing.
• Lower risk from colorant restrictions or customer preferences.

The key technical risk is dissolution. Ursodiol is poorly water-soluble, so simplification cannot compromise powder wetting, dispersion, or release. Comparative dissolution testing across pH conditions would be central to product development.[3]

2. Use a non-gelatin capsule

A hypromellose capsule could create a differentiated product for:

• Vegetarian and religious dietary requirements.
• Patients avoiding animal-derived materials.
• Institutional buyers with excipient policies.
• Export markets with specific capsule-shell requirements.

A hypromellose shell may alter moisture transfer, brittleness, fill compatibility, and dissolution behavior. The change could support a formulation patent only if the product demonstrates a defined technical effect, such as improved stability or dissolution under specified conditions. A simple substitution of gelatin with hypromellose would likely provide limited patent strength by itself.

3. Develop a liquid suspension for dysphagia and pediatric use

The strongest formulation opportunity is an oral ursodiol suspension. Capsules are difficult for young children, patients with swallowing impairment, and some elderly patients. A suspension could support weight-based dosing and reduce dose manipulation.

Key excipient categories would include:

• Suspending agents such as xanthan gum, microcrystalline cellulose and carboxymethylcellulose systems, or other pharmaceutically accepted rheology modifiers.
• Wetting agents to improve ursodiol dispersion.
• Buffers to control pH.
• Sweeteners and flavors for adherence.
• Preservatives if the product is multidose and aqueous.
• Chelators or antioxidants if stability data support their use.
• Packaging designed to limit sedimentation, microbial contamination, and dosing error.

The principal development problems are sedimentation, redispersibility, dose uniformity, microbial control, chemical stability, and palatability. A suspension that remains uniform after ordinary patient handling would have more commercial value than one that merely contains a different sweetener or flavor.

4. Consider a powder for reconstitution

A dry powder for reconstitution could reduce aqueous stability and preservative requirements. It would also permit longer shelf life before dispensing. The commercial disadvantages are preparation errors, pharmacy handling, post-reconstitution dating, and the need to demonstrate adequate redispersion.

This platform may be attractive for pediatric specialists and hospitals, but it has less convenience than a ready-to-use suspension.

What patents protect Actigall and its formulations?

Actigall’s core active ingredient, ursodiol, is an established small molecule with no practical composition-of-matter exclusivity. Commercial protection therefore depends on product-specific formulation, manufacturing, or method-of-use claims.

Patent categories relevant to ursodiol products

Patent category	Potential claim scope	Strategic strength
Active ingredient	Ursodiol itself	Very low for a mature molecule
Capsule composition	Excipient ratios, particle size, dissolution	Low to moderate unless technically distinctive
Oral suspension	Suspending system, stability, dose uniformity	Moderate if supported by robust data
Pediatric formulation	Palatability, concentration, dosing device	Moderate, with limited market scope
Manufacturing process	Milling, granulation, blending, encapsulation	Moderate if difficult to design around
Method of use	Specific liver or biliary indications	Variable and dependent on enforceability
Device or packaging	Metering syringe, bottle, reconstitution system	Usually narrow but commercially useful

The most defensible formulation patent would need more than a list of conventional excipients. It would typically require a defined composition linked to measurable performance, such as improved dissolution, reduced sedimentation, extended stability, or improved dose uniformity.

FDA Orange Book status should be assessed by current NDA and patent-listing records rather than by legacy Actigall marketing materials. Actigall’s commercial position is generally understood as mature and genericized, with no widely recognized active patent barrier comparable to a recently launched specialty drug.[2] Patent diligence should cover the reference NDA, later ursodiol products, formulation patents, and any litigation involving specific generic applicants.

When does Actigall lose exclusivity?

Actigall has already moved beyond the commercial exclusivity phase associated with a newly approved small-molecule product. The relevant market question is not the date of a future loss of exclusivity, but the remaining commercial value of the reference brand versus generic and alternative dosage-form products.

Exclusivity type	Actigall position
New chemical entity exclusivity	Expired or no longer commercially relevant
Orphan-drug exclusivity	Not the primary barrier for the established product
Pediatric exclusivity	No current commercial significance identified
Patent exclusivity	No generally recognized active barrier to routine generic entry
Regulatory exclusivity	Generic entry is governed principally by FDA approval requirements
Brand protection	Brand recognition, physician familiarity, and supply reliability

The reference product can retain value through prescribing inertia, pharmacy substitution rules, clinical familiarity, and availability in a preferred strength. Those factors are weaker than patent exclusivity and can erode when a low-cost generic or more convenient formulation enters the market.

What is the FDA regulatory status and Orange Book position?

Actigall is an FDA-approved prescription product. Ursodiol products are approved in multiple dosage forms and strengths, including capsules and tablets.[1,2]

For a conventional generic capsule, the likely route is an ANDA referencing the relevant listed drug. A materially different suspension, dosage form, or delivery system may require a separate 505(b)(2) strategy rather than a standard ANDA, depending on the reference product and the proposed labeling.[4]

Regulatory pathways

Product concept	Likely FDA pathway	Main regulatory issue
Equivalent 300 mg capsule	ANDA	Bioequivalence and product quality
Equivalent 250 mg or 500 mg tablet	ANDA, if suitable reference exists	Strength-specific equivalence
New ready-to-use suspension	505(b)(2) or other applicable pathway	Clinical bridging, stability, dose uniformity
Dry powder for reconstitution	505(b)(2) or ANDA depending on reference	Reconstitution performance and labeling
Pediatric device-enabled product	505(b)(2) or supplement strategy	Dose accuracy and usability

FDA inactive-ingredient databases can help screen excipient precedent, but they do not eliminate the need for product-specific safety, stability, and bioequivalence work.[5]

What generic entry risks exist for Actigall?

Generic entry risk is high for standard ursodiol capsules and tablets because:

1. Ursodiol is a mature active ingredient.
2. The primary products use conventional oral dosage forms.
3. The reference formulation does not depend on a complex delivery technology.
4. The molecule has broad manufacturing familiarity.
5. Patent protection is not the main commercial barrier.

Risk is lower for a technically differentiated liquid product with strong stability, dose-uniformity, and patient-use data. A suspension can still be copied, but practical development barriers are higher than for a conventional capsule.

Generic launch scenarios

Scenario	Expected competitive effect
Additional conventional capsule	Price pressure and pharmacy substitution
Low-cost tablet entrant	Greater strength and dosage-form competition
Ready-to-use suspension	Premium pricing in pediatric and dysphagia segments
Specialty pharmacy supply program	Retention of high-value prescribers
Contract-manufactured branded generic	Rapid market entry with limited fixed investment
Excipient-reduced or allergen-positioned product	Niche differentiation rather than broad protection

Which companies are challenging Actigall commercially?

The principal competitive group is generic ursodiol manufacturers rather than companies developing biosimilars or novel molecular competitors. Competition may include manufacturers of ursodiol capsules and tablets, specialty pharmaceutical companies, compounding pharmacies, and developers of oral suspensions.

A complete company-by-company challenge list requires current FDA product records and market-share data. Publicly available labeling establishes the existence of generic ursodiol products, but it does not reliably disclose commercial volume, net pricing, contract status, or launch intentions.[1,2]

What commercial opportunities exist in Actigall excipients?

Pediatric and dysphagia markets

The best opportunity is a palatable, accurately metered suspension supported by stability and usability data. A 30-day or 90-day multidose presentation with an oral syringe could improve adherence and reduce capsule manipulation.

Institutional and specialty pharmacy supply

Hospitals and specialty pharmacies may value:

• Reliable supply of ursodiol.
• Standardized liquid dosing.
• Reduced compounding workload.
• Clear storage and beyond-use instructions.
• Packaging that minimizes medication errors.

Clean-label and regional formulation

A capsule without artificial colorants, titanium dioxide, or animal-derived gelatin could support targeted positioning. This is more likely to generate modest price differentiation than broad market exclusivity.

Manufacturing and intellectual-property barriers

The strongest defensible manufacturing concepts may involve:

• Narrow particle-size distribution.
• Controlled wetting and dispersion.
• High-load capsule filling.
• Improved suspension redispersibility.
• Long-term stability in multidose packaging.
• A validated dose-measuring system.
• Reduced variability between manufactured lots.

Process patents can be valuable when they produce a reproducible technical advantage and are difficult to design around. Trade-secret protection may be more practical for blending, milling, and suspension-processing parameters.

How does Actigall compare with other ursodiol products?

Attribute	Actigall capsule	Generic capsule	Ursodiol tablet	New suspension
Regulatory familiarity	High	High	High	Moderate
Patient convenience	Moderate	Moderate	Moderate	High for dysphagia
Patent strength	Low	Low	Low to moderate	Moderate if technically differentiated
Development cost	Low for equivalent product	Low to moderate	Low to moderate	Moderate to high
Price potential	Brand premium	Low	Low to moderate	Moderate to high
Pediatric suitability	Limited	Limited	Limited	High
Manufacturing complexity	Low	Low	Moderate	High
Generic substitution risk	High	Direct competition	High	Lower initially

Key Takeaways

• Actigall contains ursodiol and is a mature small-molecule product with limited remaining exclusivity value.
• Conventional capsules and tablets are exposed to generic competition.
• The most attractive excipient opportunity is a stable, palatable, accurately metered oral suspension.
• Hypromellose capsules and excipient-reduced formulations can support niche differentiation but are unlikely to create strong standalone barriers.
• Formulation patents require demonstrated technical effects, not merely conventional excipient substitutions.
• A 505(b)(2) strategy may be appropriate for a materially different suspension or delivery system.
• Commercial value is more likely to come from convenience, supply reliability, pediatric usability, and specialty-pharmacy positioning than from the Actigall brand itself.
• The product is not subject to biosimilar competition.

Frequently Asked Questions

Can ursodiol be formulated without gelatin?

Yes. A hypromellose capsule can replace gelatin, subject to compatibility, moisture, dissolution, stability, and regulatory testing.

Is ursodiol suitable for an oral suspension?

Yes, but the formulation must address poor aqueous solubility, sedimentation, redispersibility, microbial control, palatability, and dose uniformity.

Could a new Actigall suspension receive patent protection?

Yes. Protection is more credible where the suspension has a defined composition and demonstrated technical advantages, such as improved stability, redispersion, dissolution, or dosing accuracy.

Does Actigall have biosimilar risk?

No. Actigall contains a chemically synthesized small molecule. Competitive products are generics or alternative ursodiol formulations, not biosimilars.

What is the highest-value excipient development target?

A ready-to-use ursodiol suspension with strong palatability, long in-use stability, low sedimentation, reliable syringe dosing, and pediatric labeling support offers the clearest commercial opportunity.

References

1. U.S. Food and Drug Administration. (n.d.). Actigall (ursodiol) capsules prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2018). Dissolution testing of immediate release solid oral dosage forms: Guidance for industry. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2020). Applications covered by section 505(b)(2). https://www.fda.gov/

5. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/